Omeros (NASDAQ:OMER) Share Price Passes Above 200 Day Moving Average – Here’s Why

Shares of Omeros Corporation (NASDAQ:OMER) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $9.71 and traded as high as $10.06. Omeros shares last traded at $9.81, with a volume of 1,080,894 shares traded.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. Wall Street Zen lowered Omeros from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. HC Wainwright raised their price target on shares of Omeros from $20.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, January 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Omeros in a report on Thursday, January 22nd. Finally, D. Boral Capital reissued a “buy” rating and issued a $36.00 price objective on shares of Omeros in a research report on Tuesday, January 27th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $40.33.

Omeros Price Performance

The stock has a market capitalization of $695.53 million, a P/E ratio of -4.86 and a beta of 2.45. The company’s 50-day simple moving average is $11.44 and its 200-day simple moving average is $9.71.

Insider Transactions at Omeros

In related news, CAO David J. Borges sold 30,000 shares of Omeros stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $12.31, for a total transaction of $369,300.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 12.90% of the company’s stock.

Institutional Trading of Omeros

A number of hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in shares of Omeros by 19.9% during the 4th quarter. Vanguard Group Inc. now owns 4,013,315 shares of the biopharmaceutical company’s stock worth $68,929,000 after acquiring an additional 666,357 shares during the period. UBS Group AG raised its stake in Omeros by 213.5% in the 4th quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company’s stock valued at $38,180,000 after acquiring an additional 1,513,893 shares during the period. Geode Capital Management LLC lifted its holdings in Omeros by 6.3% during the 4th quarter. Geode Capital Management LLC now owns 1,631,350 shares of the biopharmaceutical company’s stock valued at $28,026,000 after purchasing an additional 95,979 shares during the last quarter. State Street Corp lifted its holdings in Omeros by 26.9% during the 4th quarter. State Street Corp now owns 1,573,526 shares of the biopharmaceutical company’s stock valued at $27,025,000 after purchasing an additional 333,798 shares during the last quarter. Finally, Two Sigma Investments LP boosted its position in Omeros by 39.3% during the third quarter. Two Sigma Investments LP now owns 933,314 shares of the biopharmaceutical company’s stock worth $3,827,000 after purchasing an additional 263,095 shares during the period. 48.79% of the stock is owned by institutional investors and hedge funds.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.